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Left Ventricular Endocardial
Stimulation for Severe Heart Failure
Pierre Bordachar, MD,* Nicolas Derval, MD,* Sylvain Ploux, MD,* Stephane Garrigue, MD,†
Philippe Ritter, MD,* Michel Haissaguerre, MD,* Pierre Jaïs, MD*
Bordeaux, France
Biventricular resynchronization, a therapy recommended for patients presenting with left ventricular (LV) dys-
function and ventricular dyssynchrony, requires the implantation of an LV lead, usually placed in a lateral or pos-
terolateral tributary of the coronary sinus. Despite important progress made in the development of dedicated
instrumentation, the procedure remains sometimes challenging and unsuccessful in a minority of patients. In
the rare instances of unsuccessful transvenous implantations occurring in the presence of major surgical contra-
indications, a few operators have implanted the LV lead transseptally, an approach limited by technical difficul-
ties and by the thromboembolic risk associated with the presence of a lead inside the LV cavity. The interest in
this approach was recently renewed by 2 studies in an animal model and in humans, respectively, which both
found a distinctly superior hemodynamic performance associated with endocardial compared with epicardial
stimulation. This review discusses the advantages and disadvantages of LV endocardial stimulation, examines
the various techniques of LV endocardial stimulation, and projects their future applications in light of these
highly promising recent results. The implementation of endocardial stimulation will ultimately depend on: 1) the
development of safe, effective, and durable instrumentation, and reliable and reproducible intraprocedural meth-
ods to identify the optimal site of stimulation; and 2) the completion of controlled trials confirming the superior-
ity of this technique compared with standard cardiac resynchronization therapy. (J Am Coll Cardiol 2010;56:
747–53) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.038h
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riventricular resynchronization therapy is recommended for
atients presenting with left ventricular (LV) dysfunction
nd ventricular dyssynchrony (1,2). It requires the implan-
ation of an LV lead, usually placed in a lateral or postero-
ateral tributary of the coronary sinus. Despite important
rogress made in the development of dedicated instrumen-
ation, the procedure remains sometimes challenging, and
ay even be unsuccessful for various reasons, including an
nusual position or angulation of the coronary sinus, ab-
ence of wide enough veins, instability of the lead, high
apture threshold, or phrenic stimulation (3–5). In case of
nsuccessful placement through the coronary sinus, the lead
s usually implanted onto the LV epicardium through
horacotomy or thoracoscopy (6,7). The surgical approach
ay be associated with a high morbidity and mortality in
atients suffering from advanced heart failure. In the rare
ases of unsuccessful transvenous implantation in presence
f major surgical contraindications, a few operators have
mplanted the LV lead through a transseptal approach
8–16).
rom *Bordeaux University 2 and University Medical Center of Bordeaux, Bordeaux,
rance; and †Clinique Saint-Augustin, Bordeaux, France. The authors have reported
hat they have no relationships to disclose.e
Manuscript received December 2, 2009; revised manuscript received February 22,
010, accepted April 13, 2010.A review of the literature suggests that 100 patients
ave undergone transseptal procedures, which remain
imited by technical difficulties due to the lack of appro-
riate instrumentation and by the thromboembolic risk
ssociated with the presence of a lead inside the LV
avity. Despite these limitations, this technique has
everal advantages, including: 1) access to all regions of
he left ventricle; 2) a faster impulse propagation in the
ndocardial than in the epicardial ventricular layers,
llowing, at least theoretically, a faster LV depolarization;
nd 3) an apparently more physiologic LV stimulation,
reserving the transmural activation and repolarization
equence. The interest in this approach was recently
enewed by 2 studies, which reported a distinct hemody-
amic superiority associated with endocardial stimulation
ompared with epicardial stimulation (17,18). Since the
ain limitation of cardiac resynchronization therapy
CRT) is the predictable proportion of nonresponders,
ny new technique allowing a lowering of the percentage
f nonresponses is welcome. The importance of the
esults of these 2 studies raises the issue of alternatives to
oronary sinus pacing, including the future role of LV
ndocardial stimulation in candidates for CRT. This
eview discusses the advantages and disadvantages of LV
ndocardial stimulation, examines the various techniques
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and projects their future appli-
cations in light of these highly
promising recent results.
Rationale for LV
Endocardial Pacing
Limiting factors. Transseptal,
transapical, and transaortic stim-
ulation are techniques limited by
thromboembolic complications
and by complex repeat proce-
ures to manage lead infections or fractures. Furthermore,
he implantation of a transseptal lead adds the risks associ-
ted with its position across the mitral valve.
hromboembolic complications. The risk of thrombus
n the lead, which may form regardless of the lead position
nside the cardiovascular system, is a major concern with
his type of technique (19). Embolization from a right
entricular lead is the cause of pulmonary embolism (20).
owever, embolization from the left ventricle is the source
f considerably more serious systemic complications, in-
luding cerebrovascular accident. In addition, the presence
f an atrial septal orifice may be the source of paradoxical
mbolization, facilitated by pulmonary hypertension, often
resent in patients suffering from heart failure.
The few patients who have undergone the deliberate
mplantation of LV endocardial leads all received heparin
uring the procedure, and systemic anticoagulation therapy
or the long term. While their low number precludes the
rawing of firm conclusions, 2 cases of thromboembolic
omplications have been reported after the inappropriate
iscontinuation of anticoagulation therapy by the patients
9,10). In contrast, large numbers have been reported of
nadvertent implantation of LV stimulation lead through a
atent foramen ovale. In a review of the literature, van
elder et al. (21) found that the diagnosis of lead misplace-
ent was made after thromboembolic complications in
pproximately one-third of cases. It is likely, however, that
ome asymptomatic patients who received LV endocardial
eads remained undetected, and that complications associ-
ted with accidental implantations of endocardial leads are
nder-reported, as implanting physicians might not will-
ngly declare their failures. Therefore, the true incidence of
hromboembolic complications associated with the inadver-
ent implantation of a lead inside the left ventricle is
nknown. Furthermore, since these implants are involun-
ary and undetected, the majority of these patients are not
iven anticoagulation therapy.
The risks associated with the implantation of an LV
timulation lead mandates several precautionary measures.
irst, the implantation procedure must be performed during
ffective heparinization, increasing the risk of post-
rocedural hematoma, and mandating meticulous hemosta-
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
dP/dtmax  maximum rate
of rise of left ventricular
pressure
dP/dtmin  minimum rate
of rise of left ventricular
pressure
LV  left ventricularis with an electric scalpel. Second, long-term systemicnticoagulation therapy must be instituted, with its risks of
nappropriate discontinuation or excessive doses and hem-
rrhagic complications. The level of anticoagulation repre-
enting an optimal compromise between hemorrhagic and
hrombogenic risk remains to be defined, and the develop-
ent of new anticoagulants might facilitate the long-term
are of these patients. Third, instrumentation must be
hosen that has the lowest thrombogenic properties. Thin
eads made of polyurethane might be preferred. Fourth,
uring transseptal catheterization, a precise concordance
etween the size of the lead and that of the interatrial septal
rifice might facilitate the closure of the interatrial commu-
ication and lower the risk of paradoxical embolization.
nteraction with the mitral valve. An LV lead implanted
y the atrial transseptal approach crosses the mitral valve
Fig. 1). The interference of the lead with the valve,
ncluding increased risk of insufficiency and endocarditis in
ase of infectious complications, may be a major concern.
ricuspid insufficiency sometimes complicates the implan-
ation of leads in the right ventricle. Recipients of CRT
ystems often present with variable degrees of mitral insuf-
ciency due to ischemic heart disease or annular dilation.
he few case reports of transseptal lead implantation have
ot described an increase in the grade of mitral insufficiency
8–16). The use of thin leads might lower the risk of
nterference between lead and valve.
However, the risk of mitral valve endocarditis is a
onsiderably greater concern, particularly with the rise in the
ncidence of infections observed in recent years. The contact
f an infected lead with the valve may promote the devel-
pment of mitral valve endocarditis, as occurs with the
ricuspid valve, exposing the patient to systemic emboliza-
ion of vegetations. The risks of secondary infectious foci
nd cerebral or renal abscess appear far greater than the risks
Figure 1 Transseptal Passage of a
Left Ventricular Endocardial Lead
Transseptal passage of a left ventricular endocardial lead (arrow) and absence
of adhesion at the level of the mitral valve (green star), in a cardiac resynchro-
nization therapy recipient who died suddenly from a ventricular tachyarrhythmia.
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August 31, 2010:747–53 LV Endocardial Stimulationssociated with similar complications occurring in the right
ide of the heart. The need to proceed with surgical
reatment of the mitral valve may have catastrophic conse-
uences when performed in patients in severe heart failure,
t highest operative risk.
isks associated with extraction of the cardiac resynchro-
ization system. Because of the risk of systemic emboliza-
ion of vegetations, thrombi, or fibrous material surrounding
he lead, percutaneous procedures seem excessively risky.
he standard instrumentation available is poorly adapted to
xtract LV endocardial leads, notably with its lack of valves
o prevent the introduction of air during the procedure.
urthermore, as described with the tricuspid valve during
ead extractions from the right heart, the procedure might
e complicated by serious injury inflicted to the interatrial
eptum and the mitral valve (22). A surgical intervention
ould, therefore, have to be performed systematically,
espite the few published reports of uncomplicated percu-
aneous extractions (23).
dvantages of LV Endocardial Stimulation
espite the significant limitations described earlier, com-
ared with the standard approach through the coronary
inus, LV endocardial stimulation offers several notable
dvantages. First, the transseptal access allows a choice of
he site of stimulation, as opposed to a lead implant through
he coronary sinus, where the site is often imposed by
natomical constraints. This choice allows an optimization
f the capture threshold, a step that might be challenging
hen the lead is placed in a coronary sinus tributary. In
resence of a high capture threshold, the lead can easily be
aneuvered to a different site, which is often technically
ifficult inside the cardiac venous network. Phrenic nerve
timulation is not a concern, as a wide choice of sites is
vailable. Furthermore, the incidence of lead dislodgement
hould be lower than when the lead is in a cardiac vein, and
e similar to that observed after the implantation of active
xation leads in the right atrium or ventricle.
Second, the monitoring of cardiac function by a sensor
mbedded in the stimulating lead is the object of active
esearch (24,25). The prevention of cardiac decompensation
s a priority for individual patients and for public health in
eneral. The data are currently acquired by a lead placed in
he right ventricle, providing indirect information with
espect to LV contraction. The implantation of a lead inside
he left ventricle allows the direct measurement of LV
ontraction, which better reflects the hemodynamic status,
llowing more precise adjustments in case of progressive
egradation of contractile function, and a more accurate
rediction and prevention of cardiac decompensation.
Third, LV endocardial stimulation appears more physi-
logic and might be less arrhythmogenic than epicardial
timulation. In some patients, the onset of LV epicardial
timulation causes the development of polymorphous ven-
ricular arrhythmias, as it reverses the transmural activation dequence and delays the depolarization and repolarization of
he endocardium (26–28). In animal models, this reversal is
he source of heterogeneous conduction and increased
ransmural dispersion of repolarization, which is a mecha-
ism of re-entrant arrhythmias. The shift from endocardial
oward epicardial stimulation increases the transmural dis-
ersion of repolarization and the duration of the QT
nterval and, in vulnerable patients, increases the risk of
eveloping torsades de pointes. A normal transmural acti-
ation sequence associated with LV endocardial simulation
ight, therefore, lower the risk of developing arrhythmias.
Fourth, standard biventricular resynchronization is asso-
iated with a predictable approximately 30% rate of nonre-
ponse to therapy. Thus far, a single study, conducted in our
nstitution, compared 17 recipients of leads implanted
hrough the coronary sinus with 8 patients stimulated
hrough transseptal LV endocardial leads (29). At 6 months
f follow-up, echocardiography showed less ventricular
yssynchrony, greater LV shortening fraction, and a higher
elocity-time integral with endocardial than with epicardial
V stimulation. The conclusions of this limited, nonran-
omized study must be interpreted cautiously.
onfirmation of the superiority of endocardial stimulation
n the dog. A recent hemodynamic study by van Deursen et
l. (17), which showed a highly significant superiority of LV
ndocardial compared with epicardial stimulation, rekindled
he interest in this treatment method. In 8 dogs, which had
ndergone ablation of the left bundle branch, hemodynamic
unction associated with single-site LV stimulation was
ompared with that associated with biventricular stimula-
ion using 8 LV epicardial sites and 8 corresponding LV
ndocardial sites. The measurements included maximum
nd minimum rate of increase of LV pressure (dP/dtmax,
P/dtmin), stroke work, electrical dyssynchrony, and disper-
ion of repolarization. Several observations were made in
his study. First, compared with epicardial, endocardial
timulation was associated with more normal activation,
itigating the overall and transmural dispersion of repolar-
zation, and preserved the physiologic direction of activation
rom endocardium to epicardium. Although not an objec-
ive of this study, its results suggested that, as previously
ublished, endocardial stimulation might be less arrhyth-
ogenic than epicardial stimulation. Second, as observed
reviously, epicardial stimulation, compared with spontane-
us rhythm, mitigated ventricular dyssynchrony and short-
ned the duration of ventricular activation. Endocardial
timulation conferred additional benefits, and further short-
ned significantly the duration of ventricular activation and
RS complex. This greater mitigation of ventricular dys-
ynchrony by endocardial stimulation, an effect probably key
n the long-term outcome of CRT, could be explained by a
aster endocardial than epicardial conduction and a smaller,
entral endocardial than epicardial circumference. Third,
ompared with the corresponding epicardial site, endocar-
ial stimulation was associated with a 90% increase in
P/dtmax and 50% increase in stroke work. Fourth, when
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LV Endocardial Stimulation August 31, 2010:747–53timulating at the LV epicardium, wide variations in the
emodynamic response were observed depending on the site
f stimulation, with a significantly greater benefit conferred
y apical compared with basal stimulation. In contrast, the
emodynamic response was similar among the various
ndocardial sites of stimulation that were tested. Likewise,
he hemodynamic benefit was less dependent on the opti-
ization of the atrioventricular delay when stimulating
rom the endocardium than from the epicardium.
Although this study was performed in a model of acute
eft bundle branch block relatively distant from the clinical
nd electrophysiologic characteristics of patients with heart
ailure, its results are important and show unequivocally the
uperiority of endocardial stimulation on hemodynamic
easurements measured invasively. They need to be con-
rmed in an animal model of chronic heart failure with
ardiac dyssynchrony, then in patients who are candidates
or CRT.
hort-term hemodynamic study of endocardial stimulation
n patients with heart failure. We recently completed a
hort-term hemodynamic study that compared standard
picardial stimulation through the coronary sinus with LV
ndocardial stimulation (18). To study a homogeneous
opulation, we included 35 patients presenting with non-
schemic cardiomyopathies and with the usual criteria for
he implantation of a CRT system. They underwent hemo-
ynamic studies to compare dP/dtmax, dP/dtmin, pulse pres-
ure, and LV end-diastolic pressure during single-site LV
timulation from the base, the mid-endocardial septum, the
nterior, lateral, and inferior endocardial walls, and from the
picardial lateral wall through the coronary sinus and its
pposite endocardial site. The results of this comparative
tudy are important. First, we found a wide interindividual
isparity in the location of the optimal versus least favorable
ite of stimulation, such that a predictably best, or least
avorable, site was not identified for all patients. Instead, the
istribution of optimal or least favorable sites was relatively
ven among the 11 sites tested. For example, LV epicardial
ateral wall stimulation was associated with the greatest
emodynamic benefit in 9% of patients and the least benefit
n 17% of patients. Second, the choice of stimulation site
ad variable effects among CRT recipients. Whereas in
ome patients the hemodynamic variations were modest
egardless of the site tested, major intraindividual variations
ere observed in other patients, depending on the site of
timulation, with, in some cases, opposite responses, such
hat dP/dtmax was decreased by stimulation at 1 site and
arkedly increased at another. Third, on average, optimi-
ation of the site of stimulation contributed a significant
enefit to all measurements made. Stimulation of the lateral
all from a coronary sinus tributary was associated, on
verage, with a 15% increase compared with control rhythm,
ersus 30% when stimulating at the optimal site. Therefore,
search for an optimal site allowed a doubling of the
emodynamic benefits compared with standard epicardial
timulation of the lateral LV wall. These observations are tmportant for patients who derive no hemodynamic benefit
rom epicardial LV lateral wall stimulation, in whom at least
site might be successful. Fourth, we found that approxi-
ately 10% of patients are not improved regardless of the
ite of stimulation, perhaps representing the true short-term
onresponders to CRT. Fifth, the comparison between
picardial and endocardial stimulation at a same site showed
significant benefit contributed by endocardial stimulation
n diastolic (dP/dtmin), but not systolic (dP/dtmax) function.
These 2 studies, respectively conducted in dogs and
umans, yielded both similar and different results, the latter
xplained by different protocols. We did not study biven-
ricular stimulation. Furthermore, patients presenting with
eart failure and cardiac dyssynchrony are considerably
ifferent from a short-term animal model of dyssynchrony
ithout heart failure. While, in our study, the hemody-
amic response hinged on the choice of stimulation site, it
as similar regardless of the endocardial site tested in the
nimal model. In addition, when comparing endocardial
nd epicardial stimulation at a similar site, we observed a
enefit limited to diastolic function, whereas diastolic and
ystolic function were both improved in the animal model.
ltimately, in both studies, LV endocardial stimulation and
search for an optimal site both allowed a highly significant
nd immediate improvement in systolic and diastolic func-
ion compared with standard LV epicardial stimulation.
echnical Considerations
ransseptal LV endocardial stimulation. The placement
f a transseptal LV endocardial lead requires the puncture of
he interatrial septum, to allow the passage of the lead from
he right to the left atrium before entering the left ventri-
le through the mitral valve. The implantation of a perma-
ent transseptal LV stimulation lead has been described,
sing the superior, the inferior, or a mixed approach. We
escribed, in 1998, the first case of permanent transseptal
V stimulation, using a mixed right internal jugular and
emoral approach (8). The proximal segment of a guidewire,
laced in the left atrium through a transseptal puncture
erformed from the femoral vein, was snared by a loop
dvanced from the jugular vein. A sheath was introduced
nto the left atrium along the guidewire, and the stimulation
ead was advanced through the sheath. The technical
hallenges represented by this procedure prompted us, along
ith another group of French investigators, to proceed with
he puncture of the interatrial septum directly from the right
nternal jugular vein (9,10). The instrumentation used was
ot dedicated to this procedure, and was adapted to comply
ith the individual, anatomic circumstances. The septum
as punctured with or without the guidance of transesoph-
geal echocardiography, with a needle preformed to reach
he fossa ovalis. The lead was tunneled subcutaneously to a
re-pectoral pocket (Fig. 2). This internal jugular approach
s limited by the challenge represented by the absence of
ypical anatomic landmarks to localize the fossa ovalis, and
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August 31, 2010:747–53 LV Endocardial Stimulationy the tunnelization, with its risks of cutaneous erosion or
ead damage.
The transseptal catheterization of the left atrium is a
echnique familiar to electrophysiologists, used to perform
blations of accessory pathways, ventricular tachyarrhyth-
ias and, more recently, pulmonary veins isolation (30–32).
he septum is punctured from an inferior approach, using
he right femoral vein. Several operators have developed a
ixed approach, with the transseptal puncture performed
rom the right femoral vein, and implantation of the lead
rom the subclavian vein (11–14). The septum is punctured
ith a needle or by delivery of radiofrequency energy, and a
alloon may be used to dilate the orifice and facilitate the
assage of the lead. A wire is placed in the left atrium,
erving as a guide for the introduction of the stimulation
ead through a deflectable sheath. Regardless of the tech-
iques implemented, the procedural success is high, the
omplication rate is low, and the results published regarding
he long-term stability of the lead and capture threshold are
ncouraging.
ransaortic LV endocardial stimulation. A few case re-
orts of inadvertent LV endocardial pacing through the
ortic valve through catheterization of the axillary or sub-
lavian arteries have been published (33,34). The feasibility
nd safety of deliberately implanting a transaortic LV lead
rom the right carotid artery has been studied in a pig model
35). After 6 months of stimulation, and despite the absence
f anticoagulation, no thromboembolic complication was
bserved; aortic insufficiency, when present, remained triv-
al; and no aortic valve lesion was found on post-mortem
xamination. The long-term risk and effects of implanting a
ead across the aortic valve have not been ascertained in
umans, in whom a subclavian instead of a carotid approach
Figure 2 Fluoroscopic Views During Transseptal Implantation
Fluoroscopic views from a recipient of an atriobiventricular cardiac resynchronizatio
(A) The septum was punctured with a needle preformed to reach the fossa ovalis.
was introduced into the left atrium along the guidewire, and the stimulation lead would probably be preferred. bransapical LV endocardial stimulation. Hungarian in-
estigators have recently described transapical LV endocar-
ial stimulation through limited thoracotomy (36). Using
eldinger’s technique, active fixation leads were introduced
nto the LV cavity by puncturing the apex, positioned under
uoroscopic guidance, fixed to the endocardium, and tun-
eled toward the pulse generator pocket. Since the leads did
ot cross the mitral orifice, the risk of valvular insufficiency
as eliminated. The long-term safety and efficacy of this
echnique, performed in a limited number of patients, need
o be examined in larger studies.
uture Perspectives
he observations made in these 2 recent studies might
eopen the conversation around the future role of LV
ndocardial stimulation, from which various patient popu-
ations could theoretically benefit. First, this could benefit
atients in whom the standard epicardial approach has
ailed, who are at prohibitive surgical risk, and who repre-
ent the majority of current recipients of endocardial leads.
econd, this could benefit the 30% of nonresponders to
tandard CRT, who are in refractory heart failure and in a
herapeutic dead end, without alternate management op-
ion. While these recent observations suggest that endocar-
ial stimulation can improve hemodynamic function con-
iderably and immediately, it remains to be confirmed that
t will be associated with a clinical benefit, keeping in mind
hat, in our study, some patients whose dP/dtmax was not
ncreased by standard LV epicardial, lateral wall stimulation
ad a 80% increase when stimulated from the endocar-
ium. In the regular absence of alternate treatment available
or these patients, it appears legitimate to consider the
lanning of a trial to validate this strategy, as the expected
apy system, with the left ventricular endocardial lead implanted transseptally.
roximal segment of a guidewire was then placed in the left atrium. (B) A sheath
vanced through the sheath.n ther
The p
as adenefit seems to prevail over the disadvantages represented
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LV Endocardial Stimulation August 31, 2010:747–53y long-term anticoagulation therapy. Third, the deliberate
mplantation of an endocardial lead during a first implant of
CRT system deserves consideration. However, dedicated
nstrumentation needs first to be developed to facilitate the
mplant procedure and more broadly disseminate this strat-
gy. For the transseptal approach, instruments must be
esigned to allow the lead implantation in a single stage
rom the subclavian vein. Transapical lead implants are also
imited by the need to anticoagulate on the long-term. One
ight, however, conceive new surgically implanted epicar-
ial leads, of which the stimulation electrode only would
raverse the LV wall to stimulate the endocardium.
It is noteworthy that one cannot expect to eliminate all
onresponders because, in some patients, the response to
ndocardial stimulation remained weak regardless of the site
ested. Our results, however, suggest that the optimization
f the site of stimulation is an essential step, for which the
est invasive or noninvasive hemodynamic measurement
ill need to be defined, though no consensus has, thus far,
een reached with respect to which measurement best
redicts a clinical response.
Leadless pacing may considerably change the technical
hallenges confronting the implanting physicians (37).
ork in progress with prototypes implanted in animals
ppears promising. While this new instrumentation will
ompletely change the technical aspects of the implant
rocedures, the issue of stimulation site will persist and, in
he case of devices implanted with a view to improve
emodynamic function and alleviate the manifestations of
eart failure, the search for an optimal site will continue,
nd the putative superiority of LV endocardial versus
picardial stimulation will remain a key question.
onclusions
he implementation of endocardial stimulation will ulti-
ately depend on the development of instrumentation that
s safe and effective in the long term, on the development of
eliable and reproducible methods to identify the optimal
ite of stimulation during the procedure, and on the com-
letion of controlled trials confirming the superiority of this
echnique compared with standard CRT.
eprint requests and correspondence: Dr. Pierre Bordachar,
ospital Haut Leveque, Service Pr. Haissaguerre, Pessac 33604,
rance. E-mail: bordacharp@hotmail.com.
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